Evidence map›Paper›PMID 30587849›Full record

ArticleBritish journal of cancer2019

Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy.

Can Liu, Hua He, Xiaobing Li, Maureen A Su, Yanguang Cao

Erratum issuedOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.9field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Biomarkers for immunotherapy for treatment of glioblastoma.Journal for immunotherapy of cancer · 2020
    Review
  14. Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Can LiuDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Hua HeDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Xiaobing LiDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Maureen A SuDepartment of Microbiology, Immunology and Medical Genetics (MIMG) and Pediatrics, University of California, Los Angeles, CA, 90095, USA.
Yanguang CaoDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA. yanguang@email.unc.edu.
University of North Carolina at Chapel Hill · USChina Medical University · CNUniversity of California, Los Angeles · US

Funding

Optimizing antibody-based therapy through a system platform of pharmacokinetics-pharmacodynamics-immunodynamicsR35GM119661 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CAO, YANGUANG · 2016 to 2020
$2.1M
NIGMS NIH HHS R35 GM119661
6 · The paper itself

Abstract

backgroundAnti-PD-1 immunotherapies have shown clinical benefit in multiple cancers, but response was only observed in a subset of patients. Predicting which patients will respond is an urgent clinical need, but current companion diagnosis based on PD-L1 IHC staining shows limited predictability.

methodsA dynamic, metrics-based biomarker was developed to discriminate responders from non-responders for anti-PD-1 immunotherapy in B16F10 melanoma-bearing mice.

resultsSimilar to patients, there was considerable heterogeneity in response to anti-PD-1 immunotherapy in mice. Compared with the control group, 45% of anti-PD-1 antibody-treated mice displayed improved survival (defined as responders) and the remainder only gained little, if any, survival benefit from PD-1 blockade (non-responders). Interestingly, the dynamics of IFN-γ secretion by peripheral lymphocytes was associated with faster secretion onset (shorter lag time), stronger exponential phase, shorter time to half magnitude, and higher magnitude of secretion in responders at day 10 after tumour inoculation. To sufficiently predict responders from non-responders, IFN-γ secretion descriptors as well as phenotypic markers were subjected to multivariate analysis using orthogonal partial least-squares discriminant analysis (OPLS-DA).

conclusionsBy integrating phenotypic markers, IFN-γ secretion descriptors sufficiently predict response to anti-PD-1 immunotherapy. Such a dynamic, metrics-based biomarker holds high diagnostic potential for anti-PD-1 checkpoint immunotherapy.

Indexed as

AnimalsB7-H1 AntigenBiomarkers, PharmacologicalHumansImmunotherapyInterferon-gammaLymphocytesMelanoma, ExperimentalMiceNivolumabProgrammed Cell Death 1 ReceptorB7-H1 AntigenBiomarkers, PharmacologicalCd274 protein, mouseIFNG protein, mouseInterferon-gammaNivolumabPdcd1 protein, mouseProgrammed Cell Death 1 Receptor

Identifiers

PMID30587849
PMCPMC6353899
OpenAlexW2905673600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.